Vytrus Biotech S.A.

MC:VYT Spain Biotechnology
Market Cap
$93.15 Million
€90.75 Million EUR
Market Cap Rank
#21287 Global
#63 in Spain
Share Price
€13.00
Change (1 day)
+4.84%
52-Week Range
€2.76 - €13.00
All Time High
€13.00
About

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. The company offers Clarivine that activates skin's regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Ca… Read more

Vytrus Biotech S.A. (VYT) - Total Liabilities

Latest total liabilities as of December 2024: €3.84 Million EUR

Based on the latest financial reports, Vytrus Biotech S.A. (VYT) has total liabilities worth €3.84 Million EUR as of December 2024.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Vytrus Biotech S.A. - Total Liabilities Trend (2020–2024)

This chart illustrates how Vytrus Biotech S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Vytrus Biotech S.A. Competitors by Total Liabilities

The table below lists competitors of Vytrus Biotech S.A. ranked by their total liabilities.

Company Country Total Liabilities
Showbox Corp
KQ:086980
Korea ₩28.78 Billion
Linedata Services S.A.
PA:LIN
France €190.30 Million
Revival Gold Inc
OTCQX:RVLGF
USA $2.20 Million
Ildong Holdings Co Ltd
KO:000230
Korea ₩504.67 Billion
NEBAG NA SF 0,02
F:NWR
Germany €42.11K
Data Image Corporation
TW:3168
Taiwan NT$1.11 Billion
Hwa Sung Ind
KO:002460
Korea ₩325.72 Billion

Liability Composition Analysis (2020–2024)

This chart breaks down Vytrus Biotech S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.03 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.53 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Vytrus Biotech S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Vytrus Biotech S.A. (2020–2024)

The table below shows the annual total liabilities of Vytrus Biotech S.A. from 2020 to 2024.

Year Total Liabilities Change
2024-12-31 €3.84 Million -4.57%
2023-12-31 €4.02 Million +23.76%
2022-12-31 €3.25 Million +10.85%
2021-12-31 €2.93 Million +12.83%
2020-12-31 €2.60 Million --